Stock comparison
Exelixis
EXEL$13.4BHealthcare Market cap, Sector
Sanofi Consumer Healthcare India Limited
SANOFICONR.BO$104.05BHealthcare Market cap, Sector
Overall winner
Sanofi Consumer Healthcare India Limited
EXEL 07 SANOFICONR.BO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
EXEL0wins
7winsSANOFICONR.BO
64C
B78
74B
A89
74B
B83
58D
B77
60C
A91
71B
A86
80B
A85
Side-by-side metrics
| Metric | EXEL | SANOFICONR.BO |
|---|---|---|
| Market cap | $13.4B | $104.05B Winner |
| P/E (TTM) | Winner: 15.5x | 44.0x |
| EV/EBIT | Winner: 14.3x | 31.7x |
| ROIC (TTM) | 35.01% | 59.15% Winner |
| Gross margin | Winner: 96.44% | 68.13% |
| Net margin | Winner: 35.08% | 27.35% |
| Revenue CAGR 5y | 12.76% | 27.01% Winner |
| EPS CAGR 5y | Winner: 40.93% | 20.67% |
| Debt / Equity | 0.1x | 0.1x Winner |
| Dividend yield | 0.0% | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EXEL leads on
- P/E (TTM)15.5xvs 44.0x+65%
- EV/EBIT14.3xvs 31.7x+55%
- EPS CAGR 5y40.93%vs 20.67%+50%
- Gross margin96.44%vs 68.13%+29%
SANOFICONR.BO leads on
- Market cap$104.05Bvs $13.4B+87%
- Revenue CAGR 5y27.01%vs 12.76%+53%
- ROIC (TTM)59.15%vs 35.01%+41%
- Debt / Equity0.1xvs 0.1x+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.